新華醫療(600587.SH):擬出資4900萬元投設高新醫療器械公司
格隆匯12月30日丨新華醫療(600587.SH)公佈,公司擬與淄博高新區高創創業投資合夥企業(有限合夥)(簡稱“高創投資企業”)、熠品(貴陽)質量科技有限公司(簡稱“熠品科技公司”)、淄博產業技術研究院有限公司(簡稱“淄博產業技術研究院”)、廣東科鑑檢測工程技術有限公司(簡稱“廣東科鑑公司”)共同出資設立高新醫療器械公司,其註冊資本為1億元。
其中新華醫療出資4900萬元,持股比例為49%;高創投資企業出資3200萬元,持股比例為32%;熠品科技公司出資1300萬元,持股比例為13%;淄博產業技術研究院出資500萬元,持股比例為5%;廣東科鑑公司出資100萬元,持股比例為1%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.